Journalists

Journalists

Covering current events in science, the environment, technology and health requires a context and reliable sources that respond quickly.

¿Qué me ofrece?

When science hits the headlines, we publish reactions, explanations, and in-depth analysis from reliable sources, capturing both the evidence and the debates. Our library of science journalism resources and the briefings may be of use to you. Consult our directory of research centres.

Icono
Cómo trabajamos

We are on the lookout for any controversial information about science (embargoed or not), in order to react with the agility the media needs. Sign up to receive our embargoed contents, all under the Creative Commons licence. Find out more about how we work here.

Título qué me ofrece
What we offer you
Título cómo trabajamos
How we work

What is the status of Hipra's Spanish anticovid vaccine?

The European Medicines Agency (EMA) is still considering the approval of Hipra's SARS-CoV-2 vaccine. In mid-May, Hipra said it was ready to "have the vaccine available in a few days" following EMA approval, which it expected by the middle of this year, but which is being delayed until at least after July, as Elia Torroella, Hipra's R&D and Registration Director, explained at a breakfast briefing organised by the company today. 

Reactions: birds lose morphological diversity due to climate change

Climate change is causing a mass extinction of species, but for birds, this loss of biodiversity has wider implications. In research published in the journal Current Biology, researchers use statistical models to predict that this extinction will decrease morphological diversity among the remaining birds at a faster rate than species loss alone.

0

Reaction to a new intranasal HIV and SARS-CoV-2 vaccination device tested in animals

US researchers have designed an intranasal vaccination device that is capable of delivering immunising proteins through the mucosal surface. The research, published in Science Translational Medicine, shows that strong antibody responses against viruses such as HIV and SARS-CoV-2 have been achieved in mice and non-human primates.